All studies
RecruitingPhase III and phase IV (Integrated)Interventional

A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active-Comparator Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a stable background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)

Rheumatoid arthritis causes painful, swollen, and stiff joints. While treatments like methotrexate help many people, some continue to experience troublesome symptoms even after trying a biologic medicine known as a TNF inhibitor. This study compares two different medicines: upadacitinib (a daily tablet) and adalimumab (an injection). Both are approved treatments that calm an overactive immune system to reduce inflammation. Participants will stay on their usual methotrexate dose and receive one of the two study treatments. To keep the test fair, dummy treatments are used so neither the doctors nor the participants know which medicine is being taken. Over 12 weeks and beyond, doctors will track joint tenderness, swelling, blood test results, and daily comfort. The goal is to help doctors understand which treatment works best when a first biologic medicine has not provided enough relief.

At a glance

Status
Recruiting
Phase
Phase III and phase IV (Integrated)
Sponsor
Abbvie Deutschland GmbH & Co. KG
Enrolment target
148
Start
17 Oct 2023

What is this study about?

Rheumatoid arthritis is a long-term condition where the body's immune system mistakenly attacks the joints. This causes painful swelling, warmth, and stiffness that can make simple daily activities difficult. Many people take a standard medication called methotrexate to control their symptoms. When methotrexate alone is not enough, doctors often add a targeted biologic medicine called a TNF inhibitor.

However, these medicines do not work well for everyone. In some cases, joint pain and swelling remain severe, or the medicine causes unpleasant side effects that make it hard to continue. When this happens, doctors need to know which medicine to try next to give the person the best chance of feeling better. This study, known as SELECT-SWITCH, aims to answer that question.

The trial directly compares upadacitinib, a daily tablet from a group of drugs called JAK inhibitors, with adalimumab, an established injection treatment. Both drugs work in different ways to dial down the immune signals that trigger joint inflammation. By comparing them side-by-side, researchers hope to see which option is more effective at calming arthritis and improving quality of life for people who need a new treatment approach.

Key takeaways

  • Compares upadacitinib (a daily tablet) against adalimumab (an injection) for rheumatoid arthritis.
  • Aimed at people whose arthritis remains active despite methotrexate and one previous biologic drug.
  • Every participant receives an active medicine; no one receives only dummy treatments.
  • Checks how well joint swelling, pain, and everyday mobility improve at 12 weeks.
  • Taking part is completely voluntary and includes extra specialist medical checks.

Who may be eligible?

This study is open to adults aged 18 and older who have moderate to severe rheumatoid arthritis. To take part, you must currently be taking a stable, regular dose of methotrexate.

You must also have previously tried one biologic medicine from the TNF inhibitor group (such as etanercept, infliximab, or similar drugs) that did not work well enough to control your joints or caused side effects that meant you had to stop taking it.

You might not be eligible if you have already tried more than one TNF inhibitor, or if you have other serious health problems, such as a major ongoing infection. The research team will run health checks and review your past treatments to confirm if the trial is safe and appropriate for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have moderate to severe rheumatoid arthritis.
  3. I am currently taking a stable dose of methotrexate.
  4. I have tried one TNF inhibitor biologic medicine that either did not work well or caused side effects.
  5. I have not tried two or more different TNF inhibitor biologics in the past.
Answer every question to see your result.

What does participation involve?

If you take part, you will continue taking your regular methotrexate while receiving your assigned study medication. You will be placed by chance into one of two groups. One group takes an active upadacitinib tablet and a dummy injection. The other group takes an active adalimumab injection and a dummy tablet. Using dummy medicines ensures that neither you nor the doctors know which active medicine you are receiving, which keeps the results completely fair.

You will need to attend regular clinic appointments over at least 12 weeks, with follow-up visits afterwards. During these visits, doctors will examine your joints, take blood samples to check inflammation levels, and ask you about your pain and daily physical abilities. You will be shown how to safely take your tablets and use the injection pens at home, and the team will monitor your overall health closely throughout.

Potential risks and benefits

Taking part offers the possibility of better control over your arthritis symptoms, as well as regular, dedicated monitoring by joint specialists. However, both upadacitinib and adalimumab lower the immune system's activity, which can increase your risk of infections like colds, chest infections, or shingles. Injections can also cause mild skin redness or irritation, and blood tests will be monitored to check on your liver and blood counts. You are free to leave the trial at any time, for any reason, and doing so will not affect your normal NHS care or your relationship with your medical team.

Locations (11)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Greece
  • —
    Unverified
    Italy
  • —
    Unverified
    Portugal
  • —
    Unverified
    Germany
  • —
    Unverified
    Belgium
  • —
    Unverified
    France
  • —
    Unverified
    Romania
  • —
    Unverified
    Croatia
  • —
    Unverified
    Bulgaria
  • —
    Unverified
    Hungary
  • —
    Unverified
    Spain

Common questions

What is a 'double-dummy' study?

It means every participant receives both a tablet and an injection, but one is real and the other is a harmless dummy (placebo). This ensures nobody knows which active medicine they are taking, keeping the study fair and unbiased.

Could I end up with only a dummy medicine?

No. Everyone in this study receives an active, proven arthritis medicine—either upadacitinib or adalimumab—alongside their regular methotrexate. Nobody receives only placebos.

Do I have to stop taking methotrexate?

No. You will need to stay on your steady, regular dose of methotrexate throughout the trial.

How long will the trial last?

The main results are measured at 12 weeks to see how quickly your joints respond, though appointments and safety follow-ups will continue for several months. The study team will provide a clear timeline.

What happens if my arthritis gets worse during the study?

Your health and comfort are the top priority. If your arthritis flares up or does not improve, the doctors have safety plans in place and can adjust your treatment or withdraw you from the study.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active-…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.